Introduction Bladder cancer is a common malignancy that is an expensive cancer to treat [1]. In England, over 18,000 people are diagnosed with bladder cancer every year, of which approximately 25% are muscle-invasive bladder cancers (MIBCs) [2]. MIBC has a 50% 5-year survival rate despite radical surgery, radiotherapy and chemotherapy [3]. Cisplatin-based neoadjuvant chemotherapy (NAC) is standard of care for MIBC and is associated with a 5% absolute increase in survival rate [4, 5].
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile